Tumor drug shows promise for Tasmanian devils, pets and maybe humans

07/1/2013 | Sydney Morning Herald (Australia), The

A new plant-derived drug, EBC-46, was associated with regression or palliation in cancerous tumors in four Tasmanian devils, which have suffered massive losses to a contagious cancer. Veterinarian Jack Ayerbe, a director with the company that developed the drug, says he's used it successfully to treat some dogs and cats in his practice. Veterinarian Stephen Pyecroft, who helped develop and test the drug, says it may help treat captive devils and improve survival of their young, but it won't be a feasible treatment for wild animals. Human trials are planned as well.

View Full Article in:

Sydney Morning Herald (Australia), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Litigation
Center for Science in the Public Interest
Washington, DC
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Associate General Counsel
Patient-Centered Outcomes Research Institute
Washington, D.C , DC